FDA Approves Ventana MMR RxDx Panel to Identify Patients With dMMR Solid Tumors and pMMR Endometrial Cancer Eligible for Treatment With Pembrolizumab

FDA Approves Ventana MMR RxDx Panel to Identify Patients With dMMR Solid Tumors and pMMR Endometrial Cancer Eligible for Treatment With Pembrolizumab

header-info

The Ventana MMR RxDx Panel is the first immunohistochemistry (IHC) companion diagnostic test to aid in identifying patients whose solid tumors are deficient in DNA mismatch repair (dMMR), and who may be eligible for therapy with the PD-1 inhibitor pembrolizumab.